Cheng Wang1, Yee Han Dave Lee, Rainer Siebold. 1. Institute of Sports Medicine, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing, 100191, China.
Abstract
PURPOSE: To evaluate the current evidence for the management of septic arthritis after anterior cruciate ligament (ACL) reconstruction, the factors that affect the outcome after treatment and the retention of graft and implants. METHODS: A systematic literature search of the PubMed database was performed on septic arthritis after ACL reconstruction. A total of 301 publications were initially identified, and 17 papers were found to fulfil the criteria to be included in the review. RESULTS: There were 196 cases of septic arthritis after ACL reconstruction in over 30,000 ACL reconstructions, making the proportion of infection 0.6%. Most patients (114/123, 92.6%) had an acute or subacute infection at an average of 16.8 ± 10.5 days after ACL reconstruction. Coagulase-negative Staphylococci (CNS) was the most common organism (67/147, 45.6%) followed by Staphylococcus aureus (SA) (35/147, 23.8%); 86.9% underwent surgical treatment of which 92.8% had an average of 1.54 (up to 4) arthroscopic debridements. The group with SA infection had a higher graft removal rate (33.3%, p = 0.019), a longer antibiotic duration (35.4 days, p = 0.047) and a worse range of flexion (111.5°, p = 0.036) than the CNS group. CONCLUSIONS: CNS was the most common organism in septic arthritis after ACL reconstruction followed by SA. For most authors, arthroscopic debridement combined with intravenous antibiotic therapy was the initial treatment of choice. Antibiotic therapy with or without multiple irrigations of the joint is not recommended based on the high failure rates. Delayed diagnosis of more than 7 days or SA infection required a longer duration of antibiotic therapy and increased the likelihood for graft removal and restricted range of motion. Fungal infection and tubercular infection had a high prevalence of late diagnosis and open debridement. LEVEL OF EVIDENCE: Systematic review, Level IV.
PURPOSE: To evaluate the current evidence for the management of septic arthritis after anterior cruciate ligament (ACL) reconstruction, the factors that affect the outcome after treatment and the retention of graft and implants. METHODS: A systematic literature search of the PubMed database was performed on septic arthritis after ACL reconstruction. A total of 301 publications were initially identified, and 17 papers were found to fulfil the criteria to be included in the review. RESULTS: There were 196 cases of septic arthritis after ACL reconstruction in over 30,000 ACL reconstructions, making the proportion of infection 0.6%. Most patients (114/123, 92.6%) had an acute or subacute infection at an average of 16.8 ± 10.5 days after ACL reconstruction. Coagulase-negative Staphylococci (CNS) was the most common organism (67/147, 45.6%) followed by Staphylococcus aureus (SA) (35/147, 23.8%); 86.9% underwent surgical treatment of which 92.8% had an average of 1.54 (up to 4) arthroscopic debridements. The group with SAinfection had a higher graft removal rate (33.3%, p = 0.019), a longer antibiotic duration (35.4 days, p = 0.047) and a worse range of flexion (111.5°, p = 0.036) than the CNS group. CONCLUSIONS: CNS was the most common organism in septic arthritis after ACL reconstruction followed by SA. For most authors, arthroscopic debridement combined with intravenous antibiotic therapy was the initial treatment of choice. Antibiotic therapy with or without multiple irrigations of the joint is not recommended based on the high failure rates. Delayed diagnosis of more than 7 days or SAinfection required a longer duration of antibiotic therapy and increased the likelihood for graft removal and restricted range of motion. Fungal infection and tubercular infection had a high prevalence of late diagnosis and open debridement. LEVEL OF EVIDENCE: Systematic review, Level IV.
Authors: Robert T Burks; Matthew G Friederichs; Barbara Fink; Mark G Luker; Hugh S West; Patrick E Greis Journal: Am J Sports Med Date: 2003 May-Jun Impact factor: 6.202
Authors: Arndt P Schulz; Sebastian Götze; Hergo G K Schmidt; Christian Jürgens; Maximilian Faschingbauer Journal: Am J Sports Med Date: 2007-03-30 Impact factor: 6.202
Authors: Laurie M Katz; Todd C Battaglia; Paul Patino; William Reichmann; David J Hunter; John C Richmond Journal: Arthroscopy Date: 2008-09-13 Impact factor: 4.772
Authors: Joseph U Barker; Mark C Drakos; Travis G Maak; Russell F Warren; Riley J Williams; Answorth A Allen Journal: Am J Sports Med Date: 2009-11-13 Impact factor: 6.202
Authors: D Luis Muscolo; Lisandro Carbo; Luis A Aponte-Tinao; Miguel A Ayerza; Arturo Makino Journal: Clin Orthop Relat Res Date: 2009-02-04 Impact factor: 4.176
Authors: Philipp Schuster; Markus Geßlein; Michael Schlumberger; Philipp Mayer; Hermann Josef Bail; Jörg Richter Journal: Knee Surg Sports Traumatol Arthrosc Date: 2018-03-06 Impact factor: 4.342
Authors: Daniel Pérez-Prieto; Raúl Torres-Claramunt; Pablo E Gelber; Tamer M A Shehata; Xavier Pelfort; Joan Carles Monllau Journal: Knee Surg Sports Traumatol Arthrosc Date: 2014-11-22 Impact factor: 4.342
Authors: Samaneh Bourbour; Mohammad Emaneini; S M Javad Mortazavi; Mohamad Naghi Tahmasebi; Hooman Yahyazadeh; Mahmoud Jabalameli; Fereshteh Jabalameli Journal: Arch Bone Jt Surg Date: 2021-09
Authors: Raúl Torres-Claramunt; Pablo Gelber; Xavier Pelfort; Pedro Hinarejos; Joan Leal-Blanquet; Daniel Pérez-Prieto; Joan C Monllau Journal: Int Orthop Date: 2015-08-04 Impact factor: 3.075